Blog
RSS FeedPosted by Michael Wonder on 22 Sep 2019
Accelerating the shift toward person-generated real world evidence
19 September 2019 - Evidence generated from randomised clinical trials and other clinical studies has long been the foundation for ...
Posted by Michael Wonder on 21 Sep 2019
Humana CEO: competition and innovation lower drug prices better than just putting a cap on them
20 September 2019 - U.S. lawmakers should also include in their proposals rules that would facilitate greater competition and innovation, Humana ...
Posted by Michael Wonder on 20 Sep 2019
How an 'International Price Index' might help reduce drug prices
19 September 2019 - In gridlocked Washington, both Democrats and Republicans have signalled there's potential for a deal when it ...
Posted by Michael Wonder on 19 Sep 2019
5 people setting EU drug prices
19 September 2019 - Politic’s guide to the policy makers debating how to calculate the cost of cures. ...
Posted by Michael Wonder on 19 Sep 2019
FDA continues to take steps to fulfil its commitment to strengthen and modernise the 510(k) medical device program
19 September 2019 - The U.S. FDA today announced that, as a first step toward implementation of the recently established Safety ...
Posted by Michael Wonder on 19 Sep 2019
McConnell warns Pelosi's drug pricing plan is DOA
19 September 2019 - Senate Republicans are warning Speaker Nancy Pelosi that her much-anticipated drug pricing plan is dead and ...
Posted by Michael Wonder on 19 Sep 2019
Pelosi’s drug plan would let U.S. negotiate prices of 250 medications
19 September 2019 - Speaker Nancy Pelosi on Thursday released her long-awaited plan to curb soaring prices of prescription drugs, ...
Posted by Michael Wonder on 19 Sep 2019
Flawed evidence underpins approval of new cancer drugs
18 September 2019 - We must raise the bar to ensure real benefits for patients ...
Posted by Michael Wonder on 19 Sep 2019
Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
18 September 2019 - In this study, the investigators examined the characteristics of randomised controlled trials that supported approval of cancer ...
Posted by Michael Wonder on 19 Sep 2019
Electronic prescribing
19 September 2019 - Electronic Prescribing will provide an option for prescribers (including doctors, dentists, optometrists, midwives and nurse practitioners), and ...
Posted by Michael Wonder on 18 Sep 2019
FDA issues final guidance to address ‘gaming’ by the use of citizen petitions
18 September 2019 - Today the U.S. FDA issued the final guidance, Citizen Petitions and Petitions for Stay of Action Subject ...
Posted by Michael Wonder on 18 Sep 2019
FDA continues steps to promote innovation in medical devices that help advance patient safety through the Safer Technologies Program
18 September 2019 - Today, the Food and Drug Administration issued draft guidance titled “Safer Technologies Program for Medical Devices,” ...
Posted by Michael Wonder on 17 Sep 2019
Price controls for Medicare don't put America first
17 September 2019 - Instead of embracing drug price controls, the U.S. should pressure other nations to abandon them. ...
Posted by Michael Wonder on 17 Sep 2019
FDA takes first action under new international collaboration with Australia and Canada designed to provide a framework for concurrent review of cancer therapies, approving treatment for patients with endometrial carcinoma
17 September 2019 - The U.S. FDA is announcing Project Orbis, an initiative of the FDA Oncology Center of Excellence. ...
Posted by Michael Wonder on 16 Sep 2019
Prescription drug price gouging must stop
16 September 2019 - How big pharma can be prevented from indiscriminately raising the prices of its drugs. ...